


Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-A27D3002-A589-418C-BA59-5C83D22633E1_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M60380_04_01
 DOI Ref: i174e

© 2025 USPC
 Do not distribute

Pancuronium Bromide



$C_{35}H_{60}Br_2N_2O_4$ 732.67

Piperidinium, 1,1'-($(2\beta,3\alpha,5\alpha,16\beta,17\beta)$ -3,17-bis(acetyl oxy)androstane-2,16-diyl)bis[1-methyl]-, dibromide; 1,1'-($3\alpha,17\beta$ -Dihydroxy-5 α -androstan-2 β ,16 β -ylene)bis[1-methylpiperidinium] dibromide diacetate; 2 β ,16 β -Dipiperidino-5 α -androstane-3 α ,17 β -diol diacetate dimethobromide CAS RN[®]: 15500-66-0; UNII: U9LY9Y75X2.

DEFINITION

Pancuronium Bromide contains NLT 98.0% and NMT 102.0% of pancuronium bromide ($C_{35}H_{60}Br_2N_2O_4$), calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

- A. **▲ SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197K** ▲ (CN 1-MAY-2020)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- C. **IDENTIFICATION TESTS—GENERAL (191), Bromide**: A solution (1 in 10) meets the requirements of test B.

ASSAY

• PROCEDURE

Diluent: 0.0024 M hydrochloric acid

Mobile phase: Acetonitrile, methanol, and 0.024 M hydrochloric acid (125:200:675)

Standard stock solution: 1.0 mg/mL prepared as follows. Transfer the required quantity of [USP Pancuronium Bromide RS](#) to a suitable volumetric flask. Dissolve in 2% of the flask volume of acetonitrile, dilute with *Diluent* to volume, and sonicate for 3 min.

Standard solution: 0.1 mg/mL of [USP Pancuronium Bromide RS](#) in *Diluent*, from the *Standard stock solution*

Sample stock solution: 1.0 mg/mL prepared as follows. Transfer the required quantity of Pancuronium Bromide to a suitable volumetric flask. Dissolve in 2% of the flask volume of acetonitrile, dilute with *Diluent* to volume, and sonicate for 3 min.

Sample solution: 0.1 mg/mL of Pancuronium Bromide in *Diluent*, from the *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: Conductivity with suppression

Column: 4.6-mm \times 25-cm; 5- μ m packing L1

Temperatures

Column: 35°

Detector: 40°

Suppressor: 4-mm cationic membrane suppressor or equivalent

Suppression solution: 0.15 M tetrabutylammonium hydroxide

Suppressor flow rate: 1 mL/min

Flow rate: 0.75 mL/min

Injection volume: 25 μ L**Run time:** 2 times the retention time of pancuronium**System suitability****Sample:** Standard solution**Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 1.0%**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of pancuronium bromide ($C_{35}H_{60}Br_2N_2O_4$) in the portion of Pancuronium Bromide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response from the Sample solution r_S = peak response from the Standard solution C_S = concentration of [USP Pancuronium Bromide RS](#) in the Standard solution (mg/mL) C_U = concentration of Pancuronium Bromide in the Sample solution (mg/mL)**Acceptance criteria:** 98.0%–102.0% on the anhydrous basis**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

ORGANIC IMPURITIES**Diluent, Mobile phase, Standard stock solution, and Chromatographic system:** Proceed as directed in the Assay.

System suitability solution: 1 mg/mL of [USP Pancuronium Bromide RS](#) and 0.02 mg/mL each of [USP Pancuronium Bromide Related Compound A RS](#), [USP Pancuronium Bromide Related Compound B RS](#), [USP Pancuronium Bromide Related Compound C RS](#), and [USP Vecuronium Bromide RS](#), prepared as follows. Transfer the required amounts of the individual components to a suitable volumetric flask. Dissolve in 2% of the flask volume of acetonitrile, dilute with Diluent to volume, and sonicate for 3 min.

Standard solution: 0.01 mg/mL of [USP Pancuronium Bromide RS](#) in Diluent, from the Standard stock solution**Sample solution:** 1.0 mg/mL prepared as follows. Transfer the required quantity of Pancuronium Bromide to a suitable volumetric flask.

Dissolve in 2% of the flask volume of acetonitrile, dilute with Diluent to volume, and sonicate for 3 min.

System suitability**Samples:** System suitability solution and Standard solution[NOTE—See [Table 1](#) for the relative retention times.]**Suitability requirements****Resolution:** NLT 1.5 between pancuronium related compound B and pancuronium related compound A, and NLT 1.5 between the pancuronium related compound C and vecuronium peaks, System suitability solution**Tailing factor:** NMT 2.0, Standard solution**Relative standard deviation:** NMT 10.0%, Standard solution**Analysis****Samples:** Standard solution and Sample solution

Calculate the percentage of each impurity, including any unspecified impurity, in the portion of Pancuronium Bromide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

 r_U = peak response of each impurity from the Sample solution r_S = peak response of pancuronium from the Standard solution C_S = concentration of [USP Pancuronium Bromide RS](#) in the Standard solution (mg/mL) C_U = concentration of Pancuronium Bromide in the Sample solution (mg/mL) F = relative response factor (see [Table 1](#))

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Pancuronium related compound B	0.73	1.0	0.1
Pancuronium related compound A	0.81	1.0	0.1
Vecuronium related compound F ^a	0.9	—	—
Pancuronium	1.0	—	—
Pancuronium related compound C	1.39	1.0	0.1
Vecuronium	1.53	0.48	1.0
Any individual unspecified impurity	—	1.0	0.10
Total impurities	—	—	1.0

^a Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidi

nyl)androstan-16-yl]-1-methyl. This impurity is an acid degradation product of vecuronium bromide and not that of pancuronium bromide.

SPECIFIC TESTS

- [OPTICAL ROTATION, Specific Rotation \(781S\)](#).

Sample solution: 30 mg/mL in water

Acceptance criteria: +39° to +43°

- [WATER DETERMINATION, Method I \(921\)](#): NMT 8.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, protected from light and moisture.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Pancuronium Bromide RS](#)

[USP Pancuronium Bromide Related Compound A RS](#)

1,1'-(3 α ,17 β -Dihydroxy-5 α -androstan-2 β ,16 β -ylene) bis(1-methylpiperidinium) dibromide.

$C_{31}H_{56}Br_2N_2O_2$ 648.60

[USP Pancuronium Bromide Related Compound B RS](#)

1,1'-(17 β -Acetoxy-3 α -hydroxy-5 α -androstan-2 β ,16 β -ylene) bis(1-methylpiperidinium) dibromide.

$C_{33}H_{58}Br_2N_2O_3$ 690.63

[USP Pancuronium Bromide Related Compound C RS](#)

1,1'-(3 α -Acetoxy-17 β -hydroxy-5 α -androstan-2 β ,16 β -ylene) bis(1-methylpiperidinium) dibromide.

$C_{33}H_{58}Br_2N_2O_3$ 690.63

[USP Vecuronium Bromide RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PANCURONIUM BROMIDE	Documentary Standards Support	SM42020 Small Molecules 4

Topic/Question	Contact	Expert Committee
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 38(4)

Current DocID: GUID-A27D3002-A589-418C-BA59-5C83D22633E1_4_en-US

DOI: https://doi.org/10.31003/USPNF_M60380_04_01

DOI ref: i174e

OFFICIAL